Advances in anti-BRAF therapies for lung cancer

Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, D’Angelo, Alberto, Sirico, Marianna, Pittacolo, Matteo, Conter, Felipe Umpierre, Sobhani, Navid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068629/
https://www.ncbi.nlm.nih.gov/pubmed/33474634
http://dx.doi.org/10.1007/s10637-021-01068-8
Descripción
Sumario:Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0–3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.

Ejemplares similares